Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Bristol-Myers Squibb Co Market Cap
Based on ratings from 22 stock analysts, the Bristol-Myers Squibb Co stock price is expected to increase by 1.09% in 12 months. This is calculated by using the average 12-month stock price forecast for Bristol-Myers Squibb Co. The lowest target is $33.1 and the highest is $75. Please note analyst price targets are not guaranteed and could be missed completely.
About 22 Wall Street analysts have assignedBMY 9 buy ratings, 11 hold ratings, and 2 sell ratings. This means that analysts expect Bristol-Myers Squibb Co to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on BMY. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of BMY.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Trung Huynh UBS | Neutral | $54 | Maintains | Oct 9, 2024 |
| Carter Gould Barclays | Underweight | $43 | Maintains | Oct 7, 2024 |
| Steve Scala TD Cowen | Hold | $59 | Maintains | Oct 7, 2024 |
| Evan Seigerman BMO Capital | Market Perform | $53 | Maintains | Sep 27, 2024 |
| Evan Seigerman BMO Capital | Market Perform | $48 | Maintains | Sep 23, 2024 |
| Olivia Brayer Cantor Fitzgerald | Neutral | $50 | Reiterates | Sep 16, 2024 |
| Akash Tewari Jefferies | Hold | $51 | Maintains | Aug 28, 2024 |
| Carter Gould Barclays | Underweight | $42 | Maintains | Aug 22, 2024 |
| Steve Scala TD Cowen | Hold | $53 | Maintains | Aug 12, 2024 |
| Carter Gould Barclays | Underweight | $41 | Downgrade | Jul 29, 2024 |
| James Shin Deutsche Bank | Hold | $45 | Maintains | Jul 23, 2024 |
| Olivia Brayer Cantor Fitzgerald | Neutral | $45 | Reiterates | Jul 22, 2024 |
| Carter Gould Barclays | Equal-Weight | $41 | Maintains | Jul 10, 2024 |
| Carter Gould Barclays | Equal-Weight | $43 | Maintains | Apr 26, 2024 |
| Evan Seigerman BMO Capital | Market Perform | $48 | Maintains | Apr 26, 2024 |
| Mohit Bansal Wells Fargo | Equal-Weight | $52 | Maintains | Apr 18, 2024 |
| Steve Chesney Redburn Atlantic | Neutral | $54 | Downgrade | Feb 6, 2024 |
| Mohit Bansal Wells Fargo | Equal-Weight | $51 | Maintains | Feb 6, 2024 |
| Geoff Meacham B of A Securities | Neutral | $60 | Downgrade | Jan 3, 2024 |
| Geoff Meacham B of A Securities | Buy | $68 | Maintains | Dec 27, 2023 |
When did it IPO
1972
Staff Count
34,100
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - General
CEO
Dr. Christopher S. Boerner Ph.D.
Market Cap
$106.24B
In 2023, BMY generated $45.01B in revenue, which was a decrease of -2.50% from the previous year. This can be seen as a signal that BMY's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 09 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Bristol Myers (BMY) has gained significant attention from Zacks.com users, indicating potential investor interest that could influence the stock's future performance.
Why It Matters - Increased interest in Bristol Myers among Zacks.com users may indicate a potential shift in market sentiment, influencing stock performance and investment decisions.
Wed, 09 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Bristol Myers has received positive regulatory updates, but a wait-and-watch investment strategy is recommended.
Why It Matters - Positive regulatory updates can enhance Bristol Myers' growth potential, but a cautious approach may reflect uncertainties or risks that could impact stock performance.
Sun, 06 Oct 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Bristol Myers Squibb (BMY) presents a strong buy opportunity with a solid dividend yield, low valuation, and growth potential, particularly in neurodegenerative therapies.
Why It Matters - Frequent trading reduces returns; a buy-and-hold approach is preferable. Bristol Myers Squibb's strong dividend, valuation, and growth prospects position it as a promising investment.
Sun, 06 Oct 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - AI is transforming drug discovery in biotech and pharma, enhancing speed and success rates, which presents contrarian buying opportunities in the sector.
Why It Matters - AI's impact on drug discovery enhances efficiency and success rates, potentially leading to lucrative investments in biotech firms leveraging these advancements.
Thu, 03 Oct 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Bristol Myers Squibb (BMY) closed at $54.20, up 0.82% from the previous trading day.
Why It Matters - Bristol Myers Squibb's slight price increase indicates positive market sentiment and potential investor confidence, which could influence future trading and investment decisions.
Thu, 03 Oct 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - The U.S. FDA has approved the perioperative treatment using Neoadjuvant Opdivo (nivolumab) and chemotherapy, followed by surgery and adjuvant Opdivo for Bristol-Myers Squibb ($BMY).
Why It Matters - FDA approval of Opdivo enhances Bristol-Myers Squibb's oncology portfolio, potentially increasing revenue and market share, positively influencing stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
